Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23472619 | 0.84 | CRHR1 (0.37) | L3MBTL1TLR8TLR7CYP3A4KDM4E | |
| SCHEMBL23472140 | 0.83 | TLR8 (0.44) | L3MBTL1TLR8TLR7CYP3A4KDM4E | |
| SCHEMBL17035543 | 0.82 | L3MBTL1 (0.63) | L3MBTL1TLR8TLR7 | |
| SCHEMBL23472583 | 0.81 | TLR8 (0.42) | L3MBTL1TLR8TLR7CYP3A4KDM4E | |
| SCHEMBL17035558 | 0.80 | TLR8 (0.54) | L3MBTL1TLR8TLR7KDM4ENPSR1 | |
| SCHEMBL20219757 | 0.79 | TLR7 (0.39) | L3MBTL1TLR8TLR7CYP3A4CYP1A2 | |
| SCHEMBL27631266 | 0.78 | TLR8 (0.43) | L3MBTL1TLR8TLR7CYP3A4NPSR1 | |
| SCHEMBL17693710 | 0.77 | ELANE (0.37) | L3MBTL1TLR8TLR7CYP3A4KDM4E | |
| SCHEMBL17693696 | 0.77 | TLR7 (0.39) | L3MBTL1TLR8TLR7CYP3A4KDM4E | |
| SCHEMBL17693694 | 0.77 | ALDH1A1 (0.37) | L3MBTL1TLR8TLR7CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284304-B2 | Substituted pyrimidines as toll-like receptor modulators | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-15 | — | — | US | disclosed |
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | DPYD, TYMP, PNP | L3MBTL1 2052/4885TLR8 842/4885TLR7 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.